The Phase III study is designed to evaluate KD019 compared to erlotinib in patients with stage IIIB/IV NSCLC who have progressed after first- or second-line chemotherapy. It incorporates an exploratory analysis using VeriStrat, a commercially available, blood-based test that is currently used to help physicians guide treatment for patients with non-small cell lung cancer. VeriStrat testing will be performed on serum samples from the study to assess the test’s utility in identifying patients with better or worse outcomes following treatment with KD019. As a multiple TKI with superior potency against wild-type EGFR, KD019 is designed to improve overall survival compared to erlotinib.  

 

“We are very pleased to work with Kadmon on this program,” says Dr. Paul Beresford, Biodesix’s vice president of business development and strategic marketing. “Our successful collaboration may bring a personalized approach to this exciting new therapy.”

 

Over the past year, Biodesix has forged multiple partnerships with biopharmaceutical companies to examine VeriStrat’s utility with innovative oncology therapies and to discover novel diagnostic tests.  

 

“This collaboration is aligned with our strategic vision to advance leading-edge science and therapies targeting multiple pathways of proliferation and survival in disease,” says Dr. John Ryan, chief medical officer of Kadmon.